A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 Monotherapy and RBM-007 in Combination With Eylea Compared to Eylea Monotherapy
Latest Information Update: 11 Dec 2023
At a glance
- Drugs Aflibercept (Primary) ; Umedaptanib pegol (Primary)
- Indications Wet age-related macular degeneration
- Focus Proof of concept; Therapeutic Use
- Acronyms TOFU
- Sponsors Ribomic
Most Recent Events
- 05 Dec 2023 Results published in a Ribomic Media Release.
- 05 Dec 2023 According to a Ribomic media release, data from this study were published in the Eye.
- 23 Mar 2022 Updated data from secondary outcomes published in the Ribomic Media Release.